Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Locally advanced prostate cancer.

E A Klein¹, P A Kupelian, R Dreicer

¹Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. kleine@ccf.org

Current Treatment Options in Oncology

|June 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.

The Prostate·2025

Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024

Same author

Informing the delivery of cancer survivorship care in rural primary care practice.

Journal of cancer survivorship : research and practice·2022

Same author

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Standard prostate cancer treatments are effective for low-risk disease. However, identifying patients needing more aggressive therapy, particularly those with extracapsular extension (ECE), remains crucial for improved outcomes.

Area of Science:

Urology
Oncology
Medical Physics

Background:

Standard treatments for localized prostate cancer include surgery, external beam radiotherapy, and brachytherapy.
These therapies are effective for low-risk prostate cancer, with similar cure rates.
Locally advanced prostate cancer presents greater treatment challenges.

Purpose of the Study:

To review current prostate cancer treatment standards.
To identify factors predicting treatment failure in localized prostate cancer.
To discuss the need for more aggressive therapies in high-risk cases.

Main Methods:

Review of standard prostate cancer therapies and risk stratification.
Analysis of factors influencing biochemical disease-free survival after radical prostatectomy.

Related Experiment Videos

Evaluation of nomograms for predicting extracapsular extension (ECE) and treatment failure.

Main Results:

For low-risk prostate cancer, cure rates are similar across standard therapies.
Pathologic stage, particularly extracapsular extension (ECE), is a key predictor of treatment failure after radical prostatectomy.
Nomograms can identify men at high risk for ECE and treatment failure.

Conclusions:

More aggressive treatment strategies are needed for prostate cancer patients with adverse histologic features like ECE.
The optimal aggressive therapy for these high-risk patients is currently unknown.